Sangeeta Goswami, M.D., Ph.D.

Peer-Reviewed Articles

1. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. e-Pub 2023. PMID: 37833193.
2. Raychaudhuri D, Singh P, Hennessey M, Tannir AJ, Chakraborty B, Natarajan SM, Goswami S. Histone Lactylation Drives CD8 T Cell Metabolism and Function. bioRxiv, 2023.
3. Goswami S#, Raychaudhuri D, Singh P, Natarajan SM, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso MD, He Z, Jindal S, Lang FF, Basu S, Sharma P#. Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nat Cancer. e-Pub 2023. PMID: 37653141 (*Co-corresponding authors).
4. Sharma P#, Goswami S#, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652-1669, 2023. PMID: 37059068 (#Co-first authors).
5. Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol 23(2):106-120, 2023. e-Pub 2022. PMID: 35697799.
6. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment outcomes in patients with metastatic renal cell carcinoma with sarcomatoid and/or rhabdoid dedifferentiation after progression on immune checkpoint therapy. Oncologist, 2023.
7. Msaouel P#, Goswami S#, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707 (#Contributed equally).
8. Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. PMID: 35290784.
9. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
10. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7):e002850, 2021. PMID: 34326169.
11. Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci 1489(1):30-47, 2021. e-Pub 2020. PMID: 33184911.
12. Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol 11:621591, 2021. PMID: 33747934.
13. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
14. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
15. Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 2020. PMID: 32554706.
16. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2019. PMID: 31873309.
17. Shi LZ#, Goswami S#, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res 7(11):1803-1812, 2019. e-Pub 2019. PMID: 31466995 (#Contributed equally).
18. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest 128(9):3813-3818, 2018. e-Pub 2018. PMID: 29905573.
19. Chen L, Yi X, Goswami S, Ahn YH, Roybal JD, Yang Y, Diao L, Peng D, Peng D, Fradette JJ, Wang J, Byers LA, Kurie JM, Ullrich SE, Qin FX, Gibbons DL. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology 5(11):e1234570, 2016. PMID: 27999749.
20. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal J, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FX. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241, 2014. e-Pub 2014. PMID: 25348003.
21. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2012. PMID: 23204236.
22. Brooke V, Goswami S, Mohanty A, Kasi PM. Aortic dissection and renal failure in a patient with severe hypothyroidism. Case Rep Med 2012:842562, 2012. e-Pub 2012. PMID: 22829842.
23. Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Song LZ, Redding D, Singh B, Sur S, Woodruff P, Dong C, Corry DB, Kheradmand F. Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma. Nat Immunol 10(5):496-503, 2009. e-Pub 2009. PMID: 19329997.
24. Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB, Kheradmand F. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 13(5):567-9, 2007. e-Pub 2007. PMID: 17450149.
25. Zhao L, Leung JK, Yamamoto H, Goswami S, Kheradmand F, Vu TH. Identification of P311 as a potential gene regulating alveolar generation. Am J Respir Cell Mol Biol 35(1):48-54, 2006. e-Pub 2006. PMID: 16484684.
26. Sharma M, Batra J, Mabalirajan U, Goswami S, Ganguly D, Lahkar B, Bhatia NK, Kumar A, Ghosh B. Suggestive evidence of association of C-159T functional polymorphism of the CD14 gene with atopic asthma in northern and northwestern Indian populations. Immunogenetics 56(7):544-7, 2004. e-Pub 2004. PMID: 15378299.

Invited Articles

1. Goswami S. KDM6Bmediated reprogramming of myeloid cells regulates the response to immuno­therapy. Nat Cancer, 2023. PMID: 37700093.
2. Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. PMID: 33811120.
3. Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24(2):123-124, 2018. PMID: 29414936.
4. Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science 357(6349), 2017. PMID: 28751597.
5. Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. Prostate 77(2):123-144, 2017. e-Pub 2016. PMID: 27679977.
6. Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 22(2):117-20, 2016. PMID: 27111907.

Abstracts

1. Goswami S. KDM6B Mediated Epigenetic Reprogramming of Intratumoral Myeloid Cells Improves Response to Immune Checkpoint Therapy in Glioblastoma. CICON 2023 7th International Cancer Immunotherapy Conference, 2023.
2. Wang J, Campbell MT, Shah AY, Goswami S, Msaouel P, Alhalabi O, Hahn AW, Kovitz CA, Jana BRP, Arajo JC, Gao J, Zurita AJ, Jonasch E, Corn PG, Tannir NM. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases. J Clin Oncol 41(6), 2023.
3. Jiang C, Alhalabi O, Haro-Silerio J, Qiao W, Shah AY, Siefker-Radtke AO, Gao J, Goswami S, Alva AS, Koshkin VS, Guo C, Campbell MT. Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV). J Clin Oncol 41(16_Suppelment), 2023.
4. Shah AY, Campbell MT, Tidwell R, Siefker-Radtke AO, Goswami S, Alhalabi O, Adriazola AC, Shaw L, Ye Y, Chen J, Yan X, Wang L, Gao J. A phase II trial evaluating combination pemetrexed and avelumab in patients with MTAP-deficient advanced urothelial cancer. J Clin Oncol 40(16), 2022.
5. Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell MT, Shah AY, Wang J, Jonasch E, Arajo JC, Wang J, Gao J, Goswami S, Msaouel P, Tannir NM. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol 40(6), 2022.
6. Andreev-Drakhlin A, Shah AY, Adriazola AC, Shaw L, Lopez L, James M, Matin SF, Alhalabi O, Gao J, Siefker-Radtke AO, Goswami S, Xiao L, Venkatesan AM, Campbell MT. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). J Clin Oncol 39(6), 2021.
7. Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang Z, Natarajan S, Xiong L, Guan B, Singh S, Saci A, Allison JP, Galsky MD, Sharma P.. Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer. Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021.
8. Msaouel P, Gao J, Yuan Y, Siefker-Radtke AO, Jonasch E, Goswami S, Amado J. Zurita, Matthew T Campbell, Amishi Yogesh Shah, Paul G. Corn, Claudia Ramos, Xiaohong Yan, Curtis Chin, Hirak Der-Torossian, Nizar M. Tannir.. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting, 2021.
9. Siddiqui B, Gheeya JS, Goswamy R, Subudhi SK, Gao J, Shah AY, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Siefker-Radtke AO, Sharma P, Tannir N. Immune Checkpoint Therapy (ICT) re-Challenge after immune-related adverse events (irAEs) in genitourinary cancers: safety and efficacy. European Society for Medical Oncology (ESMO) Virtual Congress Meeting, 2020.
10. Goswami S, Zhang X, Hao Z, Allison JP, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy. American Society of Clinical Oncology (ASCO) Annual Meeting, 2016.
11. Goswami S, Chen J, Zhao H, Zhang X, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade therapy. American Association of Clinical Research (AACR) Annual Meeting, 2016.
12. Goswami S, Shi L, Sharma P. Ezh2 affects T cell differentiation. Immuno-Oncology Young Investigator Forum, 2015.
13. Chen L, Goswami S, Yi X, Byers L, Diao L, Roybal J, Ungewiss C, Peng D, Wang J, Wistuba I, Chen L, Ullrich S, Heymach J, Kurie J, Win XF, Gibbons D. A big role in tumor immune microenvironment of a small non-coding RNA: microRNA-200. Cancer Immunol Res 3(10_Supplement), 2015.
14. Lou Y, Diao L, Byers LA, Gibbons DL, Denning W, Wang J, Papadimitrakopoulou V, Wistuba II. Goswami S, Cortiz MA, Welsh J, Kurie JM, Heymach J. Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers. American Society of Clinical Oncology (ASCO) Annual Meeting, 2014.
15. Gibbons DL, Chen L, Goswami S, Cortez MA, Ahn YH, Byers LA, Win L, Diao L, Wang J, Roybal J, Ungewiss C, Antonia SJ, Mediaville-Varela M, Suraokar MB, Welsh J, Chen L, Wistuba II, Heymach J, Kurie JM, Qin FXF. Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis. American Society of Clinical Oncology (ASCO) Annual Meeting, 2014.
16. Gibbons DL, Chen L, Goswami S, Ahn YH, Byers LA, Diao L, Wang J, Cortez A, Roybal J, Welsh J, Zhang X, Dwyer D, Yi X, Lieping C, Wistuba I, Heymach JV, Kurie JM, Qin FXF. microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis. Clin Cancer Res 20(2_Supplement), 2014.
17. Massarelli E, Erez B, Goswami S, Kurie JM. CXCR2 inhibition decreases invasion and metastasis of a KRAS/p53-mutant lung adenocarcinoma cell line in vitro and in vivo. Cancer Res 72(8_Supplement), 2012.
18. Goswami S, Ahn YH, Lin W, Mediavila-Varela M, Zhang X, Baruch E, Dwyer DW, Ungewiss C, Patel MP, Antonia S, Qin XF, Kurie JM. miR-200 suppression in tumor cells promotes metastasis by trigging intra-tumoral CD8+ T cell anergy. IDIBELL Cancer Conference on Metastasis and Angiogenesis, 2011.
19. Goswami S, Lin W, Dwyer D, Qin XF, Kurie JM. Role of Inflammatory Cells in Lung Cancer Metastasis. Keystone Symposium, 2010.
20. Goswami S, Angkasekwinai P, Shan M, Greenlee KJ, Barranco WT, Polikepahad S, Seryshev A, Sur S, Woodruff C, Dong C, Corry DB, Kheradmand F. Divergent roles of airway epithelial MMP7 and retinoic acid in experimental asthma. J Immunol 182(1):Supplement, 2009.
21. Goswami S, Barranco W, Greenlee KJ, Seryshev AB, Corry DB, Kheradmand F. Role of matrix-metalloprotease-7 in a model of experimental asthma. FASEB J, 2008.
22. Goswami S, Barranco W, Lee SL, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema. J Immunol, 2007.
23. Goswami S, Barranco W, Lee SL, Grudo A, Corry DB, Kheradmand F. An autoimmune basis in the disease pathogenesis of COPD/Emphysema. National Student Research Forum (NSRF), 2007.
24. Lee SL, Goswami S, Grumelli S, Corry DB, Kheradmand F. Elastin derived peptide mediate autoimmune basis for smoking-induced emphysema in human. American Association of Immunologists (AAI), 2006.

Book Chapters

1. Sharma A, Campbell M, Yee C, Goswami S, Sharma P. Immunotherapy of Cancer. In: Clinical Immunology: Principles and Practice. 5th Edition, 1033-1048.e1, 2019.
2. Goswami S, Allison JP, Sharma P. Novel and Other Cancer Topics of Interest: Immuno-Oncology. In: The MD Anderson Manual of Medical Oncology: Third Edition. Third Edition. The McGraw-Hill Companies, Inc, 995-1002, 2016.
3. Sharma P, Subudhi SK, Peggs K, Goswami S, Gao JJ, Quezada S, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition. 9th Edition. Hong WK, Bast R, Hait WN Wiley, 2015.
4. Massarelli E, Goswami S, Piha-Paul S. Section 1: Targets by Organ Site: Head and Neck Cancer. In: Handbook of Targeted Cancer Therapy. Wolters Kluwer, 2014.